AAV-ie enables safe and efficient gene transfer to inner ear cells

Fangzhi Tan(ShanghaiTech University), Cenfeng Chu(ShanghaiTech University), Jieyu Qi(Nantong University), Wenyan Li(Eye & ENT Hospital of Fudan University), Dan You(Eye & ENT Hospital of Fudan University), Ke Li(Chinese Academy of Sciences), Xin Chen(ShanghaiTech University), Weidong Zhao(Eye & ENT Hospital of Fudan University), Cheng Cheng(Nanjing Drum Tower Hospital), Xiaoyi Liu(ShanghaiTech University), Yunbo Qiao(Guangzhou University), Bing Su(ShanghaiTech University), Shuijin He(ShanghaiTech University), Chao Zhong(ShanghaiTech University), Huawei Li(Eye & ENT Hospital of Fudan University), Renjie Chai(Capital Medical University), Guisheng Zhong(Nantong University)
Nature Communications
August 19, 2019
Cited by 227Open Access
Full Text

Abstract

Hearing loss is the most common sensory disorder. While gene therapy has emerged as a promising treatment of inherited diseases like hearing loss, it is dependent on the identification of gene delivery vectors. Adeno-associated virus (AAV) vector-mediated gene therapy has been approved in the US for treating a rare inherited eye disease but no safe and efficient vectors have been identified that can target the diverse types of inner ear cells. Here, we identify an AAV variant, AAV-inner ear (AAV-ie), for gene delivery in mouse inner ear. Our results show that AAV-ie transduces the cochlear supporting cells (SCs) with high efficiency, representing a vast improvement over conventional AAV serotypes. Furthermore, after AAV-ie-mediated transfer of the Atoh1 gene, we find that many SCs trans-differentiated into new HCs. Our results suggest that AAV-ie is a useful tool for the cochlear gene therapy and for investigating the mechanism of HC regeneration.


Related Papers

No related papers found

Powered by citation graph analysis